Gau JP - Search Results

1

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.

Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Greil R, Mykhalska L, Bergua-Burgués JM, Cheung MC, Pinto A, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Hirata J, Jiang Y, Yan M, Lee C, Flowers CR, Salles G. Tilly H, et al. Among authors: gau jp. N Engl J Med. 2022 Jan 27;386(4):351-363. doi: 10.1056/NEJMoa2115304. Epub 2021 Dec 14. N Engl J Med. 2022. PMID: 34904799 Clinical Trial.

2

Expression of a soluble decoy receptor 3 in patients with diffuse large B-cell lymphoma predicts clinical outcome.

Chang PM, Chen PM, Hsieh SL, Tzeng CH, Liu JH, Chiou TJ, Wang WS, Yen CC, Gau JP, Yang MH. Chang PM, et al. Among authors: gau jp. Int J Oncol. 2008 Sep;33(3):549-54. Int J Oncol. 2008. PMID: 18695885

3

Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma.

Huang YC, Liu CJ, Liu CY, Pai JT, Hong YC, Teng HW, Hsiao LT, Chao TC, Gau JP, Liu JH, Hsu HC, Chiou TJ, Chen PM, Yu YB, Tzeng CH. Huang YC, et al. Among authors: gau jp. Ann Hematol. 2011 Oct;90(10):1145-51. doi: 10.1007/s00277-011-1268-2. Epub 2011 Jun 7. Ann Hematol. 2011. PMID: 21647583

4

Patients with diffuse large B cell lymphoma in partial response or stable disease after first-line R-CHOP: the prognostic value of the absolute lymphocyte count and impact of autologous stem cell transplantation.

Hung MH, Yu YB, Huang YC, Liu HT, Hong YC, Hsiao LT, Liu JH, Gau JP, Chiou TJ, Chen PM, Tzeng CH, Liu CY. Hung MH, et al. Among authors: gau jp. Ann Hematol. 2012 Dec;91(12):1907-15. doi: 10.1007/s00277-012-1536-9. Epub 2012 Aug 11. Ann Hematol. 2012. PMID: 22885989

5

Absolute lymphocyte count predicts response to rituximab-containing salvage treatment for relapsed/refractory B-cell non-Hodgkin's lymphoma with prior rituximab exposure.

Hung MH, Yu YB, Hsiao LT, Hong YC, Liu JH, Gau JP, Chiou TJ, Chen PM, Tzeng CH, Liu CY. Hung MH, et al. Among authors: gau jp. J Chin Med Assoc. 2013 Apr;76(4):195-200. doi: 10.1016/j.jcma.2012.12.003. Epub 2013 Jan 23. J Chin Med Assoc. 2013. PMID: 23557886 Free article.

6

Diminishing prognostic role of preexisting diabetes mellitus for patients with diffuse large B-cell lymphoma in the rituximab era.

Lu HJ, Huang YC, Liu CY, Hung MH, Hu MH, Wu CY, Hong YC, Hsiao LT, Gau JP, Liu JH, Hsu HC, Chiou TJ, Tzeng CH, Yu YB. Lu HJ, et al. Among authors: gau jp. Ann Hematol. 2013 Nov;92(11):1495-501. doi: 10.1007/s00277-013-1789-y. Epub 2013 May 28. Ann Hematol. 2013. PMID: 23712292

7

Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.

Huang YC, Liu CY, Lu HJ, Liu HT, Hung MH, Hong YC, Hsiao LT, Gau JP, Liu JH, Hsu HC, Chiou TJ, Chen PM, Tzeng CH, Yu YB. Huang YC, et al. Among authors: gau jp. Ann Hematol. 2013 Nov;92(11):1513-20. doi: 10.1007/s00277-013-1807-0. Epub 2013 Jun 18. Ann Hematol. 2013. PMID: 23775580

8

Prognostic factors and treatment efficacy in patients with primary diffuse large B-cell lymphoma of the bone: single institute experience over 11 years.

Liu YC, Gau JP, Yu YB, Hong YC, Yen CC, Liu CY, Chao TC, Hsiao LT, Liu JH, Chiou TJ, Tzeng CH. Liu YC, et al. Among authors: gau jp. Intern Med. 2014;53(2):95-101. doi: 10.2169/internalmedicine.53.0967. Epub 2012 Mar 1. Intern Med. 2014. PMID: 24429447 Free article.

9

Lymphocyte/monocyte ratio and cycles of rituximab-containing therapy are risk factors for hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma and resolved hepatitis B.

Wu CY, Hsiao LT, Chiou TJ, Gau JP, Liu JH, Yu YB, Wu YT, Liu CJ, Huang YC, Hung MH, Chen PM, Huang YH, Tzeng CH. Wu CY, et al. Among authors: gau jp. Leuk Lymphoma. 2015;56(8):2357-64. doi: 10.3109/10428194.2014.991922. Epub 2015 Jan 21. Leuk Lymphoma. 2015. PMID: 25459444

10

Risk of Reverse Seroconversion of Hepatitis B Virus Surface Antigen in Rituximab-Treated Non-Hodgkin Lymphoma Patients: A Large Cohort Retrospective Study.

Hsiao LT, Chiou TJ, Gau JP, Yang CF, Yu YB, Liu CY, Liu JH, Chen PM, Tzeng CH, Chan YJ, Yang MH, Huang YH. Hsiao LT, et al. Among authors: gau jp. Medicine (Baltimore). 2015 Aug;94(32):e1321. doi: 10.1097/MD.0000000000001321. Medicine (Baltimore). 2015. PMID: 26266374 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

157 results

Search Page